Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
LCTX

LCTX - Lineage Cell Therapeutics Inc Stock Price, Fair Value and News

0.92USD-0.01 (-1.08%)Market Closed

Market Summary

LCTX
USD0.92-0.01
Market Closed
-1.08%

LCTX Alerts

  • 1 major insider buys recently.

LCTX Stock Price

View Fullscreen

LCTX RSI Chart

LCTX Valuation

Market Cap

173.7M

Price/Earnings (Trailing)

-7.34

Price/Sales (Trailing)

21.7

EV/EBITDA

-5.6

Price/Free Cashflow

-7.35

LCTX Price/Sales (Trailing)

LCTX Profitability

Operating Margin

91.88%

EBT Margin

-295.30%

Return on Equity

-32.67%

Return on Assets

-21.81%

Free Cashflow Yield

-13.6%

LCTX Fundamentals

LCTX Revenue

Revenue (TTM)

8.0M

Rev. Growth (Yr)

-39.48%

Rev. Growth (Qtr)

-30.84%

LCTX Earnings

Earnings (TTM)

-23.7M

Earnings Growth (Yr)

-49.63%

Earnings Growth (Qtr)

-37.01%

Breaking Down LCTX Revenue

Last 7 days

-5.1%

Last 30 days

-15.6%

Last 90 days

-28.7%

Trailing 12 Months

-39.9%

How does LCTX drawdown profile look like?

LCTX Financial Health

Current Ratio

2.71

LCTX Investor Care

Shares Dilution (1Y)

10.94%

Diluted EPS (TTM)

-0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20248.0M000
202311.9M10.5M8.8M8.9M
20225.6M10.1M13.0M14.7M
2021666.0K684.0K751.0K445.0K
2020678.0K000
2019545.0K322.0K256.0K257.0K
20182.3M2.3M691.0K691.0K
20174.9M3.8M2.8M1.8M
20167.0M6.5M6.1M5.9M
20154.5M5.4M6.3M5.9M
20144.1M4.0M4.4M4.4M
20133.3M3.4M3.0M3.6M
20124.2M4.4M4.0M3.5M
20113.8M3.8M4.2M4.4M
201002.5M3.1M3.7M
20090001.9M

Tracking the Latest Insider Buys and Sells of Lineage Cell Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 24, 2024
culley brian m
bought
10,500
1.05
10,000
president and ceo
Feb 11, 2024
samuel george a. iii
sold (taxes)
-2,689
1.08
-2,490
general counsel/secretary
Feb 11, 2024
samuel george a. iii
acquired
-
-
6,076
general counsel/secretary
Feb 11, 2024
culley brian m
sold (taxes)
-13,830
1.08
-12,806
president and ceo
Feb 11, 2024
culley brian m
acquired
-
-
31,249
president and ceo
Feb 08, 2024
bailey don m
bought
100,001
1.04
96,155
-
Feb 06, 2024
broadwood partners, l.p.
bought
7,000,000
1.04
6,730,770
-
Feb 06, 2024
broadwood partners, l.p.
bought
-
-
-
-
Dec 29, 2023
jayasuriya anula
bought
10,900
1.09
10,000
-
Feb 11, 2023
hogge gary s.
sold (taxes)
-7,168
1.35
-5,310
svp,clinical & medical affairs

1–10 of 50

Which funds bought or sold LCTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
Beacon Capital Management, LLC
unchanged
-
4,500
22,200
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-36.1
-23,668
155,104
-%
May 16, 2024
COMERICA BANK
added
84,745
370,115
370,437
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.92
-4,063
19,745
-%
May 15, 2024
DEUTSCHE BANK AG\
reduced
-1.96
27,580
110,850
-%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-88.3
-7,616
1,439
-%
May 15, 2024
Cetera Advisor Networks LLC
sold off
-100
-33,385
-
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
reduced
-14.51
6,641
47,952
-%
May 15, 2024
Prescott General Partners LLC
unchanged
-
722,221
2,740,740
0.15%
May 15, 2024
TWO SIGMA SECURITIES, LLC
sold off
-100
-13,847
-
-%

1–10 of 49

Are Funds Buying or Selling LCTX?

Are funds buying LCTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own LCTX
No. of Funds

Unveiling Lineage Cell Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 08, 2024
broadwood partners, l.p.
22.1%
0
SC 13D/A
Jul 08, 2022
blackrock inc.
2.2%
3,755,757
SC 13G
Mar 25, 2022
broadwood partners, l.p.
20.6%
0
SC 13D/A
Feb 04, 2022
blackrock inc.
5.9%
10,008,510
SC 13G
Mar 16, 2021
broadwood partners, l.p.
21.0%
0
SC 13D/A
Feb 14, 2020
greenbelt corp /ny
0.70%
1,043,346
SC 13D/A

Recent SEC filings of Lineage Cell Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 14, 2024
8-K
Current Report
Jun 13, 2024
8-K
Current Report
May 28, 2024
4
Insider Trading
May 14, 2024
EFFECT
EFFECT
May 14, 2024
424B5
Prospectus Filed
May 14, 2024
8-K
Current Report
May 09, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report
Apr 29, 2024
DEF 14A
DEF 14A
Apr 29, 2024
ARS
ARS

Peers (Alternatives to Lineage Cell Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Lineage Cell Therapeutics Inc News

Latest updates
Defense World29 May 202407:00 am

Lineage Cell Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-30.8%1,444,0002,088,0001,246,0003,225,0002,386,0001,915,0002,998,0004,553,0005,237,000208,00068,00071,00098,000514,0001,00053,000110,00093,000-119,000333,000
Cost Of Revenue-61.7%98,000256,000169,000127,000119,000102,000235,000215,000176,000204,000985,000125,000112,00094,000123,000114,000107,00068,00052,00035,000106,000
Gross Profit-100.0%-1,832,0001,077,0003,098,0002,267,0001,813,0002,763,0004,338,0005,061,000964,0001,285,000387,000279,000420,0001,118,000453,000672,000860,000706,000947,0002,441,000
Costs and Expenses-8,105,000---9,028,000----------------
Operating Expenses-100.0%-8,194,0007,782,0008,122,0008,909,0008,452,0008,014,0008,572,00011,457,00029,202,0008,128,0007,467,0007,329,0007,858,0007,990,0008,875,00011,493,00013,621,00010,813,00011,304,00011,585,000
  S&GA Expenses16.5%4,997,0004,288,0004,041,0004,249,0004,724,0004,347,5004,422,0005,270,0008,469,0004,424,0005,317,0004,536,0003,935,0004,519,0004,504,0004,609,0006,258,0008,660,0007,087,0006,422,0005,227,000
  R&D Expenses-22.9%3,010,0003,906,0003,741,0003,873,0004,185,0004,104,5003,592,0003,302,0002,988,00024,778,0002,811,0002,931,0003,394,0003,339,0003,486,0004,266,0005,235,0004,961,0003,780,0004,882,0006,358,000
EBITDA Margin-13.4%-2.91-2.56-2.69-2.09-2.02-1.72-3.57-4.97-8.64-95.74-18.07-18.11---------
Interest Expenses100.2%2,000-1,011,000433,000382,0002,000-422,500384,00051,0001,0002,5001,000-3,0002,000--------
Income Taxes------1,803,000-41,000500,000----1,012,000------4,384,0005,520,977--
Earnings Before Taxes-39.1%-6,558,000-4,714,000-7,158,000-5,203,000-6,207,000-6,362,000-5,575,000-6,782,000-7,093,000-28,010,000-8,846,000-4,965,000-1,448,000-8,428,000-5,340,000-17,506,000-31,300,00034,912,000-45,330,00066,544,000-4,646,000
EBT Margin-13.5%-2.95-2.60-2.84-2.22-2.10-1.76-3.65-5.04-8.76-97.23-19.01-19.56---------
Net Income-37.0%-6,542,000-4,775,000-7,110,000-5,229,000-4,372,000-6,354,000-6,069,000-6,763,000-7,087,000-28,992,000-7,823,000-4,788,000-1,416,000-8,399,000-4,482,000-16,505,000-30,032,00039,310,000-44,952,00066,725,000-4,215,000
Net Income Margin-23.1%-2.96-2.40-2.63-2.09-1.99-1.79-3.76-5.03-8.72-96.67-15.97-17.44---------
Free Cashflow4.7%-5,821,000-6,110,000-5,176,000-6,524,000-11,430,000-8,287,000-5,766,000-7,159,00021,858,000-6,019,000-4,902,000-5,545,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets7.4%108101106112113124131136145175131135128108103112119125133152184
  Current Assets18.9%46.0038.0043.0048.0050.0060.0069.0074.0082.0011268.0072.0065.0044.0040.0046.0052.0058.0062.0020.0031.00
    Cash Equivalents23.0%44.0035.0031.0034.0015.0012.0025.0071.0078.0056.0061.0062.0056.0033.0033.0013.0010.009.0014.008.0018.00
  Net PPE-6.3%2.002.005.005.006.006.005.004.005.005.005.005.005.006.005.007.008.008.009.009.009.00
  Goodwill0%11.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0011.0013.0013.0013.00
Liabilities-3.9%37.0039.0039.0040.0044.0052.0054.0054.0059.0084.0012.0011.0011.0013.0013.0014.0014.0014.0017.0020.0022.00
  Current Liabilities-6.0%17.0018.0016.0016.0017.0019.0023.0025.0025.0047.009.007.007.008.008.008.007.006.006.008.009.00
Shareholder's Equity14.2%72.0063.0068.0071.0069.0072.0078.0081.0085.0091.0012012411795.0090.0098.00105111116132161
  Retained Earnings-1.7%-391-384-380-372-367-363-357-350-344-337-308-300-295-294-296-288-281-273-268-252-222
Shares Outstanding7.9%189175175174170170170170170169168161---------
Minority Interest-1.1%-1.41-1.40-1.46-1.41-1.43-1.40-1.39-1.35-1.33-1.32-1.12-1.11-1.10-1.07-1.08-1.75-1.74-1.71-1.64-1.63-1.61
Float----186---201---357---94.00---119-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations3.9%-5,783-6,019-5,037-6,268-11,242-8,303-5,480-7,06221,904-5,873-4,848-5,416-7,424-5,641-4,847-4,239-5,026-5,523-7,443-9,667-9,314
  Share Based Compensation9.7%1,1631,0601,2691,2801,0319599871,2351,1069181,1449195394945016066266197597621,440
Cashflow From Investing-100.4%-38.009,7422,12219,15915,426-5,102-40,914-97.00-46.00-146-68.00-11510,0749021786,7025,25672013,485-1942,946
Cashflow From Financing107953.8%14,021-13.008075,6281.0012296433.005139543,71911,29420,9634,81424,558503-10.00-5.0079.00-63.00606
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

LCTX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues [Abstract]  
Total revenues$ 1,444$ 2,386
OPERATING EXPENSES:  
Cost of sales98119
Research and development3,0104,185
General and administrative4,9974,724
Total operating expenses8,1059,028
Loss from operations(6,661)(6,642)
OTHER INCOME (EXPENSES):  
Interest income, net462410
(Loss) gain on marketable equity securities, net(5)40
Foreign currency transaction gain/(loss), net(354)(472)
Other income0457
Total other income (expenses), net103435
Loss before net income tax benefit(6,558)(6,207)
Provision for income tax benefit01,803
NET LOSS(6,558)(4,404)
Net loss attributable to noncontrolling interest1632
NET LOSS ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC.$ (6,542)$ (4,372)
Net loss per common share attributable to Lineage  
Basic$ (0.04)$ (0.03)
Diluted$ (0.04)$ (0.03)
Weighted-average common shares used to compute basic and diluted net loss per common share  
Basic182,909170,127
Diluted182,909170,127
Collaboration Revenues [Member]  
Revenues [Abstract]  
Total revenues$ 1,187$ 2,121
Royalties, License and Other Revenues [Member]  
Revenues [Abstract]  
Total revenues$ 257$ 265

LCTX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS  
Cash and cash equivalents$ 43,576$ 35,442
Marketable securities4550
Accounts receivable, net77745
Prepaid expenses and other current assets2,0182,204
Total current assets45,71638,441
NONCURRENT ASSETS  
Property and equipment, net2,1042,245
Operating lease right-of-use assets2,8552,522
Deposits and other long-term assets596577
Goodwill[1]10,67210,672
Intangible assets, net46,54046,562
TOTAL ASSETS108,483101,019
CURRENT LIABILITIES  
Accounts payable and accrued liabilities5,6836,270
Operating lease liabilities, current portion1,052830
Finance lease liabilities, current portion4952
Deferred revenues, current portion10,10610,808
Total current liabilities16,89017,960
LONG-TERM LIABILITIES  
Deferred tax liability273273
Deferred revenues, net of current portion18,17718,693
Operating lease liabilities, net of current portion2,0741,979
Finance lease liabilities, net of current portion7991
TOTAL LIABILITIES37,49338,996
Commitments and contingencies (Note 13)
SHAREHOLDERS' EQUITY  
Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of March 31, 2024 and December 31, 2023
Common shares, no par value, 450,000 shares authorized as of March 31, 2024 and December 31, 2023; 188,754 and 174,987 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively466,571451,343
Accumulated other comprehensive loss(2,771)(3,068)
Accumulated deficit(391,398)(384,856)
Lineage's shareholders' equity72,40263,419
Noncontrolling deficit(1,412)(1,396)
Total shareholders’ equity70,99062,023
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$ 108,483$ 101,019
[1]Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger, see Note 13 (Commitment and Contingencies) for further discussion on the Asterias Merger. To date, we have not recognized any goodwill impairment.
LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
 CEO
 WEBSITEhttps://lineagecell.com
 INDUSTRYBiotechnology
 EMPLOYEES70

Lineage Cell Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Lineage Cell Therapeutics Inc? What does LCTX stand for in stocks?

LCTX is the stock ticker symbol of Lineage Cell Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lineage Cell Therapeutics Inc (LCTX)?

As of Fri Jun 14 2024, market cap of Lineage Cell Therapeutics Inc is 173.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LCTX stock?

You can check LCTX's fair value in chart for subscribers.

What is the fair value of LCTX stock?

You can check LCTX's fair value in chart for subscribers. The fair value of Lineage Cell Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lineage Cell Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LCTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lineage Cell Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether LCTX is over valued or under valued. Whether Lineage Cell Therapeutics Inc is cheap or expensive depends on the assumptions which impact Lineage Cell Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LCTX.

What is Lineage Cell Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, LCTX's PE ratio (Price to Earnings) is -7.34 and Price to Sales (PS) ratio is 21.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LCTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Lineage Cell Therapeutics Inc's stock?

In the past 10 years, Lineage Cell Therapeutics Inc has provided -0.106 (multiply by 100 for percentage) rate of return.